560 results about "Dermatitis repens" patented technology

The present invention provides non-invasive methods for detecting, monitoring, and diagnosing skin disease and pathological skin states such as irritated skin and psoriasis. The methods include using tape stripping to analyze expression in epidermal samples, of one or more skin markers. In illustrative examples, the tape stripping is performed using pliable tape that has a rubber adhesive. Furthermore, the present invention provides methods for predicting and monitoring response to therapy for a skin disease, such as psoriasis or dermatitis. Finally, the methods can include the use of a micro array.

The invention discloses a hyaluronic acid dressing and a preparation method thereof. The dressing comprises the following components in percentage by mass: 0.01-0.3% of medium-molecular-weight hyaluronic acid, 0.01-0.5% of small-molecular-weight hyaluronic acid, 0.03-1% of allantoin, 0.1-1% of Carbomer, 2-5% of sorbitol, 0.2-1% of trehalose, 0.7-2.5% of witch hazel distillate, 0.1-0.5% of D-panthenol, 0.05-0.15% of alpha-bisabolol, 0.2-1.0% of oat glucan, 2-10% of glycerinum, 0.06-1% of water-soluble silicon wax, 0.05-0.9% of an antalkali, 0.004-0.2% of 2-methyl-4-isothiazoline-3-one, 0.05-0.4% of phenoxyethanol, 0.005-0.05% of pentanediol, 0.01-0.06% of octylene glycol, 0.025-0.5% of methylparaben and the balance of water. The dressing disclosed by the invention is capable of permeating into the deep layers of the skin to remove excessive free radicals, promoting the generations of blood vessels, and accelerating the union of wounds, in particular, acnes, eczematous dermatitis, photorejuvenation postoperation repair and the like.

A cosmetic treatment method, and a device therefor, are provided that allow for cosmetic treatment of cosmetic disorders, caused by chronological age, environmental factors, changes in physiological functions of skin, such as psoriasis, dermatitis, acne, cellulites, and viral and/or bacteriological attacks. The device comprises a nitric oxide (NO) eluting polymer arranged to contact the area to be cosmetically treated, such that a cosmetic dose of nitric oxide is eluted from said nitric oxide eluting polymer to said area. The nitric oxide (NO) eluting polymer is integrated with a carrier material, such that said carrier material, in use, regulates and controls the elution of said cosmetic dosage of nitric oxide (NO). Furthermore, a manufacturing method for said device is provided.

The present invention provides unique, efficacious, inexpensive, safe, reliable, convenient, minimally bitter, skin protecting and penetrating, easy-to-administer base compositions and active agent-containing compositions, such as those including hydrocortisone, and related production and topical application methods, for treating the skin of mammals for a wide variety of different dermatologic conditions, disorders and diseases, such as inflammation, redness, cracking, insect bites, dryness, allergic reactions, trauma, irritant dermatitis, perleche, contact dermatitis, psoriasis, eczema, seborrheic dermatitis, acne excoriate, xerosis, eczema craquele, stasis dermatitis, disease related conditions and dryness from medications such as isotretinoin, acitretin and lipid lowering agents. This is effected by topically administering, or otherwise applying, effective amounts of the compositions thereto in forms that not only address the skin and mucosa of the mouth and lips, but also of the rest of the body and, in particular, areas where other topical balms containing hydrocortisone and other active ingredients have not been developed or marketed. Additionally, the flavoring addition to this product, and the base wherein the active ingredient(s) reside, affords a significantly better tasting, and less bitter, composition, thereby allowing a more pleasant experience and better compliance by patients. Larger sized stick formulation(s) allow for more applicability of the product, and more usefulness thereof, in various areas, and mucosal skin, of the body. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in the form of a solid roll-on stick present in a variety of sizes.

The invention relates to a polycyclic derivative inhibitor as well as a preparation method and application thereof. Particularly, the invention relates to a compound represented by a general formula,the preparation method of the compound, a pharmaceutical composition containing the compound and the application of the compound as an intracellular non-receptor tyrosine kinase to mediation of signaltransduction and activation of various cell factors. The compound plays a key role in the biological process of participating in immunoregulation, immune cell proliferation and the like, is closely related to various inflammatory diseases such as rheumatoid arthritis, dermatitis, psoriasis, inflammatory bowel diseases (ulcerative colitis and Crohn's disease) and the like, and has the same substituent groups in the following general formula (I) as defined in the specification.

The invention relates to a therapeutic agent for fungal dermatitis, containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, and a composition for the treatment of fungal dermatitis, containing luliconazole or lanoconazole in a substantially dissolved state as an active ingredient.

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

The present invention generally relates to topical compositions, and particularly to a topical ointment for treatment of skin disorders and methods of use thereof The present invention recognizes that treatment of certain skin disorders can be more efficient, safe, and rapid-acting with few or no side effects. The present invention is particularly adaptable for treatment of a variety of skin disorders, such as for example, dermatitis (eczema), psoriasis and other forms of immuno-dysfunctional dermatitis. The present invention can be combined as supplement treatment to many available over-the counter and/or prescriptive products for treatment of skin disorders.

The invention provides application of a panaxadiol saponins fraction in preparing a medicine for preventing dermatitis and scar and a health-care cosmetic. The panaxadiol saponins fraction comprises the following main constituents: ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rc and ginsenoside Rd. The medicine or the cosmetic is prepared from active constituents in the single panaxadiol saponins fraction or/and other medicines together and a pharmaceutically acceptable or cosmetic acceptable carrier. The medicine or the cosmetic is prepared by utilizing raw materials: ginseng rhizome medicinal materials, American ginseng rhizome medicinal materials, ginseng stem leaf medicinal materials, American ginseng leaf medicinal materials and total extractives or total saponins of the ginseng rhizome medicinal materials, the American ginseng rhizome medicinal materials, the ginseng stem leaf medicinal materials and American ginseng leaf medicinal materials through a chromatographic separation and purification method combining macroporous resin column chromatography and octadecylsilane chemically bonded silica column chromatography. The scar can be prevented from forming while the tissue regeneration and repair are promoted by the medicine or the cosmetic. Compared with glucocorticoids, cellular immunity is integrally regulated, the drug action is stable after the medicine is suspended, and the drug action advantage is obvious. The medicine or the health-care cosmetic is highly safe. The structural formula of panaxadiol saponins is shown in the specification.